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ntegral peroxisomal membrane proteins (PMPs) are syn-
thesized in the cytoplasm and imported posttranslationally.
Here, we demonstrate that PEX19 binds and stabilizes
newly synthesized PMPs in the cytosol, binds to multiple
PMP targeting signals (mPTSs), interacts with the hydro-
phobic domains of PMP targeting signals, and is essential
for PMP targeting and import. These results show that
I
 
PEX19 functions as both a chaperone and an import receptor
for newly synthesized PMPs. We also demonstrate the
existence of two PMP import mechanisms and two classes
of mPTSs: class 1 mPTSs, which are bound by PEX19 and
imported in a PEX19-dependent manner, and class 2
mPTSs, which are not bound by PEX19 and mediate protein
import independently of PEX19.
 
Introduction
 
Peroxisomes are discrete, single membrane-bound organelles.
All peroxisomal proteins are synthesized in the cytoplasm
and imported posttranslationally, but the mechanisms used
for importing peroxisomal membrane proteins (PMPs) are
distinct from those that translocate soluble enzymes into the
peroxisome lumen (Lazarow and Fujiki, 1985; Gould and
Valle, 2000). This is reflected in the fact that most 
 
pex
 
 mu-
tants are defective in peroxisomal matrix protein import but
have no defect in PMP import (Chang et al., 1999; Hettema
et al., 2000). Also, PMPs do not use either of the two per-
oxisomal targeting signals (PTSs) that direct proteins into
the peroxisome matrix, the tripeptide PTS1, and the non-
apeptide PTS2 (Gould and Valle, 2000). The functional
properties of PMP targeting signals (mPTSs) and the mech-
anisms of PMP import remain obscure.
A common view of protein targeting signals is that they
are independent elements that have little or no role in the
protein’s ultimate structure or function. It is difficult to
reconcile this view with two well-established properties of
targeting signals for integral PMPs. First, many polytopic
PMPs contain multiple, nonoverlapping peroxisomal targeting
signals, any one of which is sufficient to direct proteins
into the peroxisome membrane (Biermanns and Gartner,
2001; Jones et al., 2001; Wang et al., 2001; Brosius et al.,
2002). Second, PMP targeting signals are large, 
 
 
 
50–100
aa in length, and the aggregate size of the targeting signals
in several PMPs comprises a significant fraction of the en-
tire protein (Sacksteder et al., 2000; Biermanns and Gart-
ner, 2001; Jones et al., 2001; Wang et al., 2001; Brosius et
al., 2002).
We recently developed a hypothesis that can explain both
the large size and functional redundancy of PMP targeting
signals in the context of posttranslational PMP import
(Jones et al., 2001). Specifically, we proposed the existence
of a cytoplasmic PMP chaperone and import receptor that
(a) binds to multiple sites along polytopic PMPs; (b) pre-
vents PMP misfolding, aggregation, and destruction in the
cytoplasm by masking their transmembrane domains; and
(c) directs newly synthesized PMPs to the peroxisome mem-
brane, and therefore plays a specific and essential role in
PMP import. Although previous works have concluded that
PEX19 cannot function as a PMP import receptor (Snyder
et al., 2000; Fransen et al., 2001). We show here that
PEX19 has all of the properties one would expect for a bi-
functional PMP chaperone/import receptor. In addition, we
establish the existence of two mechanistically distinct PMP
import pathways: one that requires PEX19 and mediates the
import of multiple PMPs; and one that is PEX19 independent
and mediates the import of PEX3.
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Results
 
PEX19 has PMP chaperone activity
 
Molecular chaperones are proteins that mediate the correct
assembly of other polypeptides but are not components of
the functional assembled structures (Ellis and Hemmingsen,
1989). However, our hypothesis of PMP import requires a
more restricted definition for the PMP chaperone. It de-
mands that the PMP chaperone reside in the cytoplasm and
both bind and stabilize newly synthesized PMPs before their
insertion into the peroxisome membrane. PEX19 is a pre-
dominantly cytosolic, partly peroxisomal protein and is re-
quired for peroxisome biogenesis (Gotte et al., 1998; Matsu-
zono et al., 1999; Sacksteder et al., 2000). Therefore, we
tested whether PEX19 binds and stabilizes PMPs in the cy-
toplasm. We examined the association of PEX19 and tran-
siently expressed, epitope-tagged PMPs, including PMP34
(Wylin et al., 1998), PEX11
 
 
 
 (Abe and Fujiki, 1998), and
PMP24 (Reguenga et al., 1999), and two control proteins,
the peroxisomal matrix protein PTE1 (Jones et al., 1999)
and the viral envelope glycoprotein VSV-G (Adams and
Rose, 1985). To simplify the analysis of PMP interactions in
the cytoplasm, we performed our experiments in cells that
lack peroxisomes and therefore cannot import PMPs: the
PEX19-deficient human fibroblast line, PBD399-TI, and a
PEX3-deficient human fibroblast line, PBD400-TI. Finally,
we elevated PEX19 levels in the PBD400-TI cells by tran-
sient transfection to ensure that they were proportional to
the levels of PMP expression in these experiments.
Immunoblot analysis revealed that integral PMPs were
much more abundant in peroxisome-deficient cells that ex-
press PEX19 than in cells that do not express PEX19 (Fig. 1
A). These results reflect the status of soluble, cytoplasmic
PMPs in detergent-free, membrane-free lysates. This was
confirmed by immunofluorescence studies which revealed
that all three PMPs shared the same cytoplasmic accumula-
tion and nuclear exclusion as PEX19 (Fig. 1 B). In contrast,
these PMPs could only rarely be detected in PEX19-defi-
cient cells, and what little could be detected was mislocalized
to the mitochondrion (unpublished data).
To determine whether the PEX19-mediated increase
in PMP abundance reflected a change in PMP half-life,
we expressed PMP34/13xmyc in the same two cell lines
(
 
 
 
PEX19 or –PEX19), pulse labeled the cells with [
 
35
 
S]me-
thionine for 1 h, and chased with excess cold methionine for
varying lengths of time. At each time point, a membrane-
free cell lysate was subjected to immunoprecipitation with
anti-myc antibodies. The levels of PMP34/13xmyc in each
sample were determined by autoradiography and by immu-
noblot with anti-myc antibodies (Fig. 1, C and D). Densito-
metric analysis revealed that PEX19 increased the half-life of
PMP34/13xmyc by 20-fold, an effect large enough to ex-
plain the PEX19-mediated increase in PMP abundance in
these cells.
To determine whether PEX19 stabilized PMPs through
physical interaction in the cytosol, we asked whether these
cytoplasmic, stable PMPs could be recovered in PEX19 im-
munoprecipitates (IPs). We coexpressed each integral PMP
with PEX19 and an epitope-tagged form of PEX19, 3xHA-
PEX19. 1 d later, the cells were lysed and subjected to im-
munoprecipitation with anti-HA antibodies. The IPs were
then separated by SDS-PAGE and immunoblotted with
anti-myc antibodies. A higher level of each PMP was de-
tected in the anti-HA IPs from cells expressing 3xHA-
PEX19 (Fig. 1 E). Furthermore, the analysis of PMP levels
in the samples before and after immunoprecipitation indi-
cated that the majority of each PMP was associated with
PEX19 (Fig. 1 F).
If PEX19 is a cytoplasmic PMP chaperone, it should also
bind newly synthesized PMPs. To test this prediction we
used PBD399 (
 
PEX19
 
-deficient) cells that stably express
3xHA-PEX19 at approximately the level of PEX19 in wild-
type cells (these cells contain normal peroxisomes and
import PMPs; unpublished data). These PBD399/3xHA-
PEX19 cells were transiently transfected with pcDNA3-
PMP34/13xmyc, pulse labeled with [
 
35
 
S]methionine and
chased with excess cold methionine for varying amounts of
time. At each time point, half of the cells were lysed, mem-
branes were discarded, and the samples were subjected to
immunoprecipitation with an anti-HA mAb. The IPs were
then solubilized with SDS, diluted, and subjected to a sec-
ond immunoprecipitation with an anti-myc mAb. The other
half of the cells were solubilized in 1% Triton X-100 and
subjected to immunoprecipitation using an anti-myc mAb.
After separation of the samples by SDS-PAGE, the labeled
PMPs were detected by autoradiography (Fig. 1 G). Densi-
tometric analysis of these films revealed that the half-time of
association between cytosolic PMP34/13xmyc and PEX19
was 
 
 
 
15 min, whereas the half-life of total PMP34/13xmyc
was 
 
 
 
300 min. Thus, PEX19 displays a kinetically re-
stricted interaction with PMPs, preferentially binding newly
synthesized PMPs in the cytosol.
 
PEX19 is an import receptor for multiple integral PMPs
 
Our hypothesis that PMP import requires a bifunctional
PMP chaperone/import receptor led us to next ask whether
PEX19 also functioned as a PMP import receptor. We first
tested whether PEX19 binds to the mPTSs of multiple
PMPs. We tested the c-terminal mPTS of PMP34 (Jones et
al., 2001), an mPTS from PEX11
 
 
 
 (Sacksteder et al., 2000),
and both reported mPTSs of PMP22 (Brosius et al., 2002).
We also tested two distinct mPTSs from PEX16, one re-
ported previously (Fransen et al., 2001) and one (amino ac-
ids 221–336) identified in our laboratory (unpublished
data). Finally, we examined three reported mPTSs of
PMP70 (Sacksteder et al., 2000; Biermanns and Gartner,
2001). PEX3-deficient PBD400-TI cells, which lack peroxi-
somes, were cotransfected with plasmids designed to express
the mPTS-containing proteins together with either PEX19
or 3xHA-PEX19. The next day the cells were lysed in hypo-
tonic buffer and membranes were discarded after centrifuga-
tion. The resulting soluble protein lysates were subjected to
immunoprecipitation with antibodies to the HA epitope tag,
followed by immunoblot with antibodies specific for the
mPTS-containing proteins. Each mPTS-containing protein
was precipitated with 3xHA-PEX19, demonstrating the
ability of PEX19 to bind these diverse mPTSs (Fig. 2 A).
As an independent, in vivo test of PEX19-mPTS binding,
we next asked whether PEX19 could control the distribution 
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of mPTS-containing proteins. We examined the mPTS-con-
taining proteins in 
 
PEX3
 
-deficient PBD400-TI cells that
were also made to express high levels of either PEX19 or
3xNLS-PEX19, a form of PEX19 that is efficiently targeted
to the nucleus (Jones et al., 2001). 1 d after transfection the
cells were fixed and the mPTS-containing proteins were lo-
calized by immunofluorescence microscopy. PEX19 accu-
mulates in the cytoplasm and is excluded from the nucleus,
whereas 3xNLS-PEX19 is excluded from the cytoplasm but
accumulates in the nucleus (Fig. 2 B). Proteins containing
the mPTSs from PMP34, PEX11
 
 
 
, PEX16, PMP22, and
PMP70 all accumulated in the cytoplasm when coexpressed
with PEX19 but accumulated in the nucleus when coex-
pressed with 3xNLS-PEX19 (Fig. 2 C), demonstrating that
PEX19-mPTS interactions can control the subcellular distri-
bution of these mPTS-containing proteins in vivo.
 
PEX19 interacts with the transmembrane region 
of PMP targeting signals
 
The hypothesis that PMP import requires a bifunctional
PMP chaperone/import receptor is rooted in the assumption
that the hydrophobic transmembrane domains of PMPs
must be masked as PMPs move through the cytoplasm to
Figure 1. Pex19 is a PMP chaperone. (A) PEX19 expression results in increased abundance of PMPs in the cytosol. PEX3-deficient human 
fibroblasts were transfected with plasmids designed to express PMP34myc, PEX11 myc, PMP24/3xmyc, VSV-G, mycPTE1, and PEX19 
( PEX19). PEX19-deficient human fibroblasts were transfected with plasmids designed to express the same test proteins and vector alone 
( PEX19). Equal total protein from a membrane-free lysate of each cell sample was analyzed by immunoblot using antibodies to the c-myc 
epitope or to VSV-G as appropriate. (B) PEX3-deficient human fibroblasts transfected with plasmids designed to express PEX19 and either 
PMP34myc, PEX11 myc, or PMP24/3xmyc were processed for indirect immunofluorescence using antibodies to the c-myc epitope (left) or 
PEX19 (right). Bar, 15  M. (C) PEX19 stabilizes PMP34/13xmyc in the cytosol. PEX3-deficient human fibroblasts were transfected with plasmids 
designed to express PMP34/13xmyc and PEX19 ( PEX19); PEX19-deficient human fibroblasts were transfected with a plasmid designed to 
express PMP34/13xmyc and empty vector ( PEX19). Cells were pulsed for 15 min with [
35S]methionine and chased with excess cold 
methionine for the times indicated. A membrane-free cell lysate of each sample was subjected to immunoprecipitation with anti-myc antibodies. 
Equal fractions of each IP were analyzed by autoradiography (
35S) and immunoblot using anti-myc antibodies (anti-myc). (D) Relative 
35S-signal 
intensities for each time point in B versus time with best fit exponential curves. ( , solid line),  PEX19; ( , dashed line),  PEX19; t1/2 ( PEX19)   
300 min; t1/2 ( PEX19)   15 min. (E) PEX19 binds multiple PMPs in the cytosol. PEX3-deficient human fibroblasts transfected with plasmids
designed to express PMP34/13xmyc, PEX11 myc, PMP24/3xmyc, and either 3xHA-PEX19 ( 3xHA-PEX19) or PEX19 ( PEX19). Equal total 
protein from a membrane-free lysate of each cell sample was subjected to immunoprecipitation with anti-HA antibodies. IPs were analyzed 
by immunoblot using anti-myc antibodies. (F) The majority of cytosolic PMP is bound to PEX19. Equal amounts of lysates of 3xHA-PEX19–
expressing cells from E sampled before (Pre-IP) and after (Post-IP) immunoprecipitation were analyzed by immunoblot using anti-myc anti-
bodies. (G) PEX19 interacts with newly synthesized PMPs. PEX19-deficient human fibroblasts stably expressing 3xHA-PEX19 were transfected 
with a plasmid designed to express PMP34/13xmyc. Cells were pulsed with [
35S]methionine for 10 min, chased with excess methionine for 
the indicated times, and split into two fractions. Membrane-free lysates of cells in the first fraction were subjected to immunoprecipitation 
with anti-HA antibodies. The samples were solubilized in SDS and subjected to a second immunoprecipitation with anti-myc antibodies. 
Immunoprecipitations were analyzed by autoradiography (PEX19-associated, 
35S) and immunoblot using anti-myc antibodies (PEX19-associated, 
anti-myc). Cells from the second fraction were solubilized in 1% Triton X-100 and subjected to immunoprecipitation using anti-myc antibodies; 
and PMP34/13xmyc was detected by autoradiography (whole-cell IP, 
35S). For PEX19-PMP34/13xmyc association, t1/2   15 min. For the 
lifetime of PMP34/13xmyc in the whole cell, t1/2   300 min. 
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the peroxisome membrane. If this is true, and if PEX19 is
the PMP chaperone/import receptor of this hypothesis, then
PEX19 should bind to subregions of mPTSs that contain
transmembrane domains. We tested this prediction using
the COOH-terminal mPTS of PMP34, which contains a
single transmembrane domain. We generated a series of
mutations in this mPTS and examined their effects on
PEX19 interaction in vivo. Truncation mutants that retained
the transmembrane domain retained their interaction with
PEX19, whereas those that lacked part of the transmem-
brane domain were no longer efficiently bound by PEX19
(Fig. 3). The smallest fragment that retained full interaction
with PEX19, PMP34aa270-307, contains a long hydropho-
bic stretch that is interrupted by a pair of charged residues
(E289 and K290). Replacement of these charged residues
with leucines inhibited the fragment’s interaction with
PEX19, as did replacement of three hydrophobic residues
with hydrophilic amino acids (LMF283-285KKK). Replac-
ing the flanking basic residues at the COOH-terminal
side of the putative transmembrane domain with acidic resi-
dues (KR302-303EE) had no substantive effect on mPTS–
PEX19 interaction. These results indicate that PEX19 inter-
acts with the transmembrane domain of the PMP34 mPTS,
and that the distribution of hydrophobic and charged resi-
dues within the transmembrane domain are important for
mPTS–PEX19 interaction.
 
Inhibition of PEX19 activity results in a defect 
in PMP import
 
The data presented thus far support the hypothesis that
PEX19 is a chaperone and import receptor for newly synthe-
sized PMPs. However, this hypothesis demands that PEX19
Figure 2. PEX19 binds multiple PMP 
targeting signals. (A) Multiple mPTSs 
coprecipitate with PEX19. PEX3-
deficient human fibroblasts were trans-
fected with plasmids designed to express 
PMP34aa244-307/3xmyc, PEX11 aa181-
259/3xmyc, PEX16aa221-336/3xmyc, 
PEX16aa59-219/3xmyc, PMP22aa1-94/
3xmyc, PMP22aa95-195/3xmyc, 
PMP70aa1-61/13xmyc, PMP70aa61-
160/13xmyc, PMP70aa1-124/3xmyc, 
and either 3xHA-PEX19 ( 3xHA-PEX19) 
or PEX19 ( PEX19). Equal total protein 
from a membrane-free lysate of each cell 
sample was subjected to immunoprecip-
itation with anti-HA antibodies. IPs were 
analyzed by immunoblot using anti-myc 
antibodies. (B) PEX3-deficient human 
fibroblasts transfected with plasmids 
designed to express PEX19 (left) or 
3xNLS-PEX19 (right) were processed 
for indirect immunofluorescence using 
antibodies against PEX19. Bar, 15  M. 
(C) PEX19 controls the subcellular 
distribution of multiple mPTSs. PEX3-
deficient human fibroblasts transfected 
with plasmids designed to express the 
mPTSs from A and either PEX19 (left) or 
3xNLS-PEX19 (right) were processed 
for indirect immunofluorescence using 
anti-myc antibodies. Bar, 15  M. 
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play a direct role in PMP import. Although the absence of
peroxisomes in PEX19-deficient cells is consistent with this
hypothesis, this phenotype could also reflect a role for
PEX19 in peroxisome division, lipid import, or peroxisome
synthesis de novo. To determine whether PEX19 plays a di-
rect role in PMP import, we used RNA interference (RNAi)
to elicit a transient inhibition of PEX19 in normal human
fibroblasts (Elbashir et al., 2001). A 21-bp siRNA duplex
corresponding to a unique sequence of human PEX19
mRNA was transfected into 5756-TI cells and levels of
PEX19 protein were followed over a span of 5 d. PEX19
protein levels were severely reduced by day two, remained
low on days three and four, and rose slightly by day five (Fig.
4 A). In contrast, the levels of two other peroxins, the im-
port receptor for peroxisomal matrix proteins, PEX5, and
the integral PMP, PEX13, were relatively unaffected. Trans-
fection with siRNA specific to PEX5 resulted in a reduction
in PEX5 protein levels, with little or no change in PEX19 or
Figure 3. PEX19 binds the transmembrane region of the PMP34 
mPTS. PEX3-deficient human fibroblasts expressing 3xNLS-PEX19 
and myc-tagged mutant forms of the COOH-terminal PMP34 mPTS 
were processed for indirect immunofluorescence using antibodies 
to the myc epitope and PEX19. (A, left) Diagram showing amino 
acid range of each truncation mutant studied. Darkened regions 
indicated relative position of the putative transmembrane domain. 
Light vertical bars indicate relative positions of the engineered point 
mutations. All proteins fused to three tandem c-myc epitopes at the 
COOH terminus. (Right) Bar graph of relative binding efficiency of 
each mutant. Relative binding efficiency is the proportion of cells 
expressing both 3xNLS-PEX19 and PMP34 mPTS mutant in which 
the PMP34 mPTS mutant is seen in the nucleus. n   100 cells for 
each sample. Values are normalized. (B) Amino acids 270-307 of 
PMP34. Putative transmembrane domain is boxed, sites of engineered 
point mutations are in bold and underlined. (C) Immunofluorescence 
images of cells expressing selected PMP34 mPTS mutants from the 
experiment in A. (Left) Anti-myc staining; (right) anti-PEX19 staining. 
Bar, 15  M.
Figure 4. Peroxisomes persist for multiple days after inhibition 
of PEX19. (A) Treatment with PEX19 and PEX5 siRNA mediates 
specific reductions in PEX19 and PEX5 levels. Wild-type human 
fibroblasts were subjected to electroporation with PEX19 siRNA 
(top) or PEX5 siRNA (bottom). Equal amounts of protein from daily 
cell samples after siRNA treatment were separated by SDS-PAGE 
and processed for immunoblot using antibodies to PEX19, PEX5, 
and PEX13. (B) Peroxisomes persist for  3 d despite inhibition of 
PEX19. Daily cell samples after treatment with PEX19 siRNA (top) 
or PEX5 siRNA (bottom) were processed for indirect immuno-
fluorescence using antibodies to the peroxisomal membrane marker 
PMP70. Bar, 15  M. 
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Figure 5. Inhibition of PEX19 causes a 
specific PMP import defect. (A) Inhibition 
of PEX19 disrupts import of PMP34 but 
not import of the peroxisomal matrix 
protein, PTE1. Wild-type human fibro-
blasts were subjected to electroporation 
with TRIP8b siRNA (top), PEX19 siRNA 
(middle), or PEX5 siRNA (bottom). Cells 
were transfected with plasmids designed 
to express HA-PTE1 and PMP34myc, 
and processed for indirect immuno-
fluorescence with antibodies to the HA 
epitope (left) or the c-myc epitope (mid-
dle). Cells showing peroxisomal import 
were counted and scored for import of 
HA-PTE1 or PMP34myc (right). Means 
and SD of three independent trials are 
presented. TRIP8b siRNA n   314; PEX19 
siRNA n   303; PEX5 siRNA n   67. 
Bar, 15  M. (B) Inhibition of PEX19 
disrupts mPTS targeting. Wild-type human 
fibroblasts were subjected to electro-
poration with TRIP8b siRNA or PEX19 
siRNA followed by transfection with 
plasmids designed to express HA-PTE1 
and either PMP34aa244-307/3xmyc 
(top) or PEX16aa221-336/3xmyc (bottom). 
Cells were processed for immuno-
fluorescence using anti-HA (left) or 
anti-myc (middle) antibodies. Cells that 
imported HA-PTE1 into peroxisomes 
were scored as to whether PMP34aa244-
307/3xmyc or PEX16aa221-336/3xmyc 
was seen in peroxisomes, seen only in 
nonperoxisomal compartments, or 
not seen (right). Means and SD of three 
independent trials are presented. 
PMP34aa244-307/3xmyc: TRIP8b 
siRNA n   306, PEX19 siRNA n   305; 
PEX16aa221-336/3xmyc: TRIP8b 
siRNA n   301, PEX19 siRNA n   306. 
Bar, 15  M. 
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PEX13 abundance. Immunofluorescence studies of cells
treated with PEX5 and PEX19 siRNAs showed numerous
peroxisomes over the first 3 d (Fig. 4 B), demonstrating that
PEX19 siRNA could be used to inhibit PEX19 in cells
that still contained peroxisomes. Prolonged treatment with
PEX19-specific siRNA caused a reduction in peroxisome
number and the loss of peroxisomes from some cells (un-
published data). This finding is consistent with the known
phenotype of PEX19-null cells, which lack peroxisomes.
Wild-type cells were treated with siRNAs specific for
 
PEX19
 
, 
 
PEX5
 
, or a control gene, 
 
TRIP8b
 
 (Chen et al.,
2001). 60 h later, the cells were transfected with a pair of
plasmids that express a PMP, PMP34myc, and a peroxi-
somal matrix protein, HA-PTE1. 100 min after transfec-
tion, the cells were fixed and processed for immunofluores-
cence to assess the import of these marker proteins. To
ensure that intact, functioning peroxisomes were present, we
examined only those cells that imported either PMP34myc
or HA-PTE1 (Fig. 5 A). Under this scheme the majority
(75%) of 
 
TRIP8b
 
-treated cells showed import of both HA-
PTE1 and PMP34myc. As expected from PEX5’s well-
established role in peroxisomal matrix protein import, inhi-
bition of PEX5 induced a selective deficit in peroxisomal
matrix protein import, with 88% of cells importing only
PMP34myc and only 12% importing HA-PTE1. The fact
that some cells imported HA-PTE1 is consistent with the
fact that our electroporation protocol used for siRNA deliv-
ery is less than 100% efficient (Chang et al., 1997). Inhibi-
tion of PEX19 induced the converse phenotype, a selective
defect in PMP import. In 
 
PEX19
 
 siRNA-treated cells, the
majority of cells (76%) imported only HA-PTE1. Interest-
ingly, rather than being distributed throughout the cytosol,
like HA-PTE1 in 
 
PEX5
 
 siRNA-treated cells, PMP34myc
was simply not seen in the majority of 
 
PEX19
 
 siRNA-treated
cells. This was likely due to degradation of PMP34myc and
is consistent with both the well-documented instability of
PMPs in the absence of PEX19 (Hettema et al., 2000; Sack-
steder et al., 2000) and the stabilizing effect of PEX19 on
PMP34 observed in Fig. 1 G.
To quantify these effects we analyzed the phenotypes of
hundreds of cells from each population and from a minimum
of three trials. When no attempt is made to correct for the
siRNA transfection efficiencies, the data show that inhibition
of PEX19 caused a fourfold reduction in PMP import,
whereas inhibition of PEX5 caused an eightfold reduction in
matrix enzyme import. When one does correct for the appar-
ent siRNA transfection efficiency (88%, the inverse of the
percent of cells transfected with 
 
PEX5
 
 siRNA that still import
peroxisomal matrix proteins), 
 
PEX19
 
 siRNA appears to cause
a 
 
 
 
10-fold reduction in PMP import.
Next, we tested whether the observed PMP import de-
fect in cells treated with 
 
PEX19
 
 siRNA would hold true
for mPTSs. We treated wild-type cells with 
 
PEX19
 
 and
 
TRIP8b
 
 siRNAs, waited 60 h, and transfected the cells
with plasmids that express HA-PTE1 and either
PMP34aa244-307/3xmyc or PEX16aa221-336/3xmyc.
Next, we assayed for import of the mPTS-containing pro-
teins by identifying cells that had imported HA-PTE1 and
scoring the distribution of the mPTS-containing protein in
those cells as either peroxisomal (if any peroxisomes were
identified), nonperoxisomal (if no peroxisomes were iden-
tified), or not seen (Fig. 5 B). Scoring those cells that ef-
fectively imported HA-PTE1 ensured that only those
cells with peroxisomes able to import matrix proteins
were counted in this analysis of PMP import. Both
PMP34aa244-307/3xmyc and PEX16aa221-336/3xmyc
were imported into peroxisomes in the majority of control
cells (88% and 91%, respectively). In 
 
PEX19
 
 siRNA-
treated cells, however, both mPTS-containing proteins
were imported poorly. Specifically, only 12% of cells im-
ported PMP34aa244-307/3xmyc and only 22% imported
PEX16aa221-336/3xmyc. Of special interest here is that,
rather than being degraded like full-length PMP34myc,
PMP34aa224-337/3xmyc was mistargeted to other com-
partments of the cell in the majority of 
 
PEX19
 
 siRNA-
treated cells. This result provides direct evidence that inhi-
bition of PEX19 function disrupts PMP import not only
by destabilizing PMPs but also by preventing appropriate
PMP targeting.
 
A second PMP import pathway
 
The hypothesis that PEX19 is a PMP chaperone and import
receptor contrasts with previous observations that PEX19
does not bind to the mPTS of PEX3, another integral PMP
(Kammerer et al., 1998; Soukupova et al., 1999; Snyder et
al., 2000; Fransen et al., 2001). Therefore, we tested
whether PEX19 functioned as a chaperone and import re-
ceptor for PEX3 (Fig. 6). Using the same assays that showed
strong interaction between PEX19 and other mPTSs, we
found that the PEX3 mPTS (PEX3aa1-50/6xmet3xmyc) is
neither bound by PEX19 (Fig. 6 B) nor is its subcellular dis-
tribution affected by PEX19 or 3xNLSPEX19 (Fig. 6 C).
Rather, the PEX3 mPTS was targeted to mitochondria in
cells that lack peroxisomes, as reported previously for PEX3
and the PEX3 mPTS (Soukupova et al., 1999; Sacksteder et
al., 2000).
These results suggested that the PEX3 mPTS might repre-
sent a second, distinct class of mPTS. To test this hypothe-
sis, we assayed the effect of PEX19 inhibition on the activity
of the PEX3 mPTS. Normal human fibroblasts (5756-TI)
were treated with either 
 
PEX19
 
 siRNA or 
 
TRIP8b
 
 siRNA,
transfected with plasmids that express HA-PTE1 or the
PEX3 mPTS, and processed for immunofluorescence. We
identified those cells that had imported HA-PTE1 and
scored whether or not they had imported the PEX3 mPTS.
In contrast to the results with other mPTS-containing pro-
teins, PEX19 inhibition had no effect on the targeting of the
PEX3 mPTS (Fig. 6 D). These results suggest that there are
at least two classes of functionally distinct mPTSs: class 1
mPTSs, which require PEX19 function, and class 2 mPTSs,
which function independently of PEX19.
 
Discussion
 
Integral PMPs are synthesized on cytosolic ribosomes and
imported into peroxisomes posttranslationally. We and oth-
ers have shown that polytopic PMPs contain multiple tar-
geting signals, each of which is sufficient for insertion into 
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the peroxisomal membrane (Biermanns and Gartner, 2001;
Jones et al., 2001; Wang et al., 2001; Brosius et al., 2002).
To explain these features of PMP import, we proposed pre-
viously the existence of a cytosolic, PMP-specific chaperone
and import receptor that (a) binds PMPs at multiple sites;
(b) masks their hydrophobic transmembrane domains and
prevents their misfolding, aggregation, and premature de-
struction; and (c) directs them to the peroxisome membrane
(Jones et al., 2001).
PEX19 is a predominantly cytoplasmic, partly peroxi-
somal protein (Gotte et al., 1998; Matsuzono et al., 1999;
Sacksteder et al., 2000); and we have shown here that
PEX19 binds and stabilizes newly synthesized PMPs in the
cytoplasm by interacting with their hydrophobic mem-
brane-spanning domains. We have also shown that PEX19
binds the targeting signals of class 1 PMPs and is required
for class 1 PMP import. These results demonstrate a direct
and specific role for PEX19 in PMP import, that of a cyto-
plasmic PMP chaperone and a PMP import receptor.
This conclusion is supported by the prior observations
that PEX19–PMP interactions can be detected with purified
PMPs (Sacksteder et al., 2000) and in yeast two-hybrid sys-
tems (Gotte et al., 1998; Sacksteder et al., 2000; Snyder et
al., 2000; Fransen et al., 2001), as well as the observation
that PEX19 binds to all PMPs regardless of their function
(Gotte et al., 1998; Sacksteder et al., 2000; Snyder et al.,
2000; Fransen et al., 2001). Furthermore, PEX19 function
appears to be specific to PMP import, as transient inhibition
of PEX19 has no effect on peroxisomal matrix protein im-
port and permanent loss of PEX19 in yeast and human cells
Figure 6. The mPTS of PEX3 functions 
via a PEX19-independent pathway. 
(A) The first 50 aa of PEX3 are sufficient 
for peroxisomal targeting. Wild-type 
human fibroblasts were transfected with 
a plasmid designed to express the PEX3 
mPTS (PEX3aa1-50/6xmet3xmyc) and 
cells were processed for immunofluores-
cence using antibodies to the c-myc 
epitope (left) or PMP70 (right). Bar, 15 
 M. (B) The mPTS of PEX3 does not co-
precipitate with PEX19. PEX3-deficient 
human fibroblasts were transfected with 
plasmids designed to express the PEX3 
mPTS and either 3xHA-PEX19 ( 3xHA-
PEX19) or PEX19 ( PEX19). Equal total 
protein from a membrane-free lysate 
of each cell sample was subjected to 
immunoprecipitation with antibodies to 
the HA epitope. IPs (top) and whole cell 
lysates (bottom) were processed for 
immunoblot using anti-myc antibodies. 
(C) The subcellular distribution of the 
PEX3 mPTS is not affected by PEX19. 
PEX3-deficient human fibroblasts were 
transfected with plasmids designed to 
express the PEX3 mPTS and either PEX19 
(top) or 3xNLS-PEX19 (bottom). Cells 
were processed for indirect immuno-
fluorescence using anti-myc (left) or 
anti-PEX19 (right) antibodies. Bar, 15 
 M. (D) Inhibition of PEX19 does not 
affect peroxisomal targeting of the PEX3 
mPTS. Wild-type human fibroblasts 
were subjected to electroporation with 
either TRIP8b siRNA (top) or PEX19 
siRNA (bottom). Cells were transfected 
with plasmids designed to express HA-
PTE1 and the PEX3 mPTS. Cells were 
processed for immunofluorescence using 
antibodies to the HA epitope (left) or the 
c-myc epitope (middle). Cells importing 
HA-PTE1 were scored as to whether the 
PEX3 mPTS was seen in peroxisomes, 
seen only in nonperoxisomal compart-
ments, or not seen (right). Means and SD 
of three independent trials are presented. 
TRIP8b siRNA n   311; PEX19 siRNA 
n   294. Bar, 15  M.PEX19 is a PMP chaperone and import receptor | Jones et al. 65
generates peroxisome-specific cellular phenotypes (Gotte et
al., 1998; Matsuzono et al., 1999; Sacksteder et al., 2000).
In this paper, we found that PEX19 does not bind the
mPTS of PEX3 and that inhibition of PEX19 has no effect
on its import into peroxisomes. These results suggest that
PEX3 uses a distinct type of mPTS and a distinct import
mechanism from the majority of PMPs. The fact that PEX3
contains a distinct mPTS may be related to its essential role
in peroxisome membrane biogenesis. In both human cells
and yeast, loss of PEX3 results in the absence of detectable
peroxisomes and the rapid proteolysis of integral PMPs
(Hettema et al., 2000; South et al., 2000). This and other
observations have fueled speculation that PEX3 might me-
diate peroxisome formation from some other organelle,
perhaps the ER (Baerends et al., 1996; Salomons et al.,
1997; Kammerer et al., 1998; Kunau and Erdmann, 1998;
Titorenko and Rachubinski, 1998), or might even catalyze
de novo peroxisome synthesis (South et al., 2000, 2001).
These models all imply that PEX3 occupies an early and cen-
tral role in peroxisome membrane biogenesis, and our obser-
vation that PEX3 is imported by a mechanism that is distinct
from that of several other PMPs is consistent with this possi-
bility. Whether PEX3 is the sole class 2 PMP remains to be
determined. PEX16 is the only other PMP known to be es-
sential for peroxisome membrane biogenesis, but PEX19
does interact with both mPTSs from PEX16 and is required
for the peroxisomal import of at least one of them.
The identification of PEX19 as a chaperone and import
receptor for class-1 PMPs opens several areas for future in-
vestigation. For example, does PEX19 recognize newly syn-
thesized PMPs cotranslationally at the ribosome or does a
more general chaperone mediate the transfer of nascent
PMPs from the protein synthesis machinery to PEX19?
Also, what is the precise nature of PEX19–mPTS interac-
tions? The extreme hydrophobicity of the known mPTSs
has retarded our development of a quantitative in vitro
PEX19–mPTS interaction assay, but such assays are clearly
needed before we can truly understand the PEX19–mPTS
interaction. The observation that a small fraction of PEX19
is found at peroxisome membranes (Sacksteder et al., 2000;
Snyder et al., 2000) suggests that PEX19, together with
other factors, might also participate in the insertion of PMPs
into the peroxisome membrane. Of chief interest will be the
improvement of our understanding of the relationship be-
tween PEX19 and PEX3.
It should be noted that some previous works have claimed
that PEX19 cannot function as either a cytosolic chaperone
or a PMP import receptor. Our results allow a fresh inter-
pretation of many of the data used to support this opposing
conclusion. Snyder et al. (2000) claimed that PEX19 cannot
function as a cytosolic chaperone for newly synthesized
PMPs. They based this conclusion on their inability to de-
tect PEX19–PMP interactions in steady-state cross-linking
experiments from cytosolic fractions. Aside from the general
problems inherent in making conclusions solely from nega-
tive results, Snyder et al. (2000) failed to consider the differ-
ences in the steady-state abundance of PMPs in the cyto-
plasm as opposed to their steady-state abundance in the
peroxisome membrane. This difference reflects the short
half-time of import for PMPs ( 3 min; Imanaka et al.,
1996) relative to their half-life ( 5 h; Fig. 1 G) and may be
sufficient to explain the Snyder et al. (2000) result.
Reports have also claimed that PEX19 cannot function as
an import receptor for newly synthesized PMPs (Snyder et
al., 2000; Fransen et al., 2001). This claim is based largely on
the observations that PEX19 does not bind all known
mPTSs and that PEX19 has been observed to bind PMPs at
locations distinct from known mPTSs. However, without
additional information, this data can only be interpreted as
evidence against a role for PEX19 as an import receptor if
one assumes (a) that there is only one PMP import mecha-
nism and therefore only one class of mPTS; and (b) that
PMPs contain one and only one mPTS. Both of these as-
sumptions are problematic. The first assumption flies in the
face of many precedents in the field of cell biology, including
the existence of two peroxisomal targeting signals and recep-
tors for peroxisomal matrix proteins, and is refuted by the
finding of two distinct classes of mPTSs in this paper. It is
also now clear that many PMPs contain multiple mPTSs.
Thus, the binding of PEX19 to a region of a PMP other than
a known mPTS may simply suggest the presence of an addi-
tional, not yet identified, mPTS. As for the reported discor-
dance between PEX19 binding sites and mPTSs in the yeast
PMPs PEX10, PEX13, PEX22, and PEX17 (Snyder et al.,
2000), and the human PMP PEX12 (Fransen et al., 2001),
this discordance is based only on uncontrolled, negative re-
sults from two-hybrid assays using large protein fusions of
unknown integrity. Thus, it is unclear whether these proteins
lack a class 1 mPTS and are imported independently of
PEX19 or whether more rigorous investigations would reveal
them to also be class I PMPs. We are hopeful that the siRNA
assays developed here for mammalian cells, or similar assays
using temperature-sensitive mutants in yeast, will serve to
distinguish between those PMPs whose import is PEX19 de-
pendent and those whose import is PEX19 independent.
Another argument used to claim that PEX19 is not an im-
port receptor for PMPs is that PEX19 sometimes binds to
fragments of proteins or mutations thereof that do not func-
tion as mPTSs (Snyder et al., 2000; Fransen et al., 2001).
However, this argument is also flawed, for it assumes (a) that
the binding of a PMP to its import receptor is sufficient to
mediate all facets of its localization, including both its tar-
geting to the peroxisome surface and its insertion into the
peroxisome membrane; and (b) that there is only one form
of PEX19–PMP interaction. There is no evidence to support
the first assumption, nor is there any a priori basis for this
assumption. In fact, the mechanistic differences between im-
port receptor-ligand binding and membrane protein inser-
tion processes provide a compelling a priori basis for the op-
posite conclusion: correct PMP targeting likely requires
mPTSs that possess multiple functional domains, only one
of which mediates its binding to its cognate import receptor.
For instance, other functional domains might mediate inter-
action with factors at the peroxisome surface or might be re-
quired for proper insertion in the peroxisome membrane.
Disruption of these elements during a mutation analysis
study would result in a failure to import, although receptor
binding might be maintained. As for the second assumption,
it seems likely that an import receptor, in addition to its in-
teractions with its cargo, would also interact with factors at66 The Journal of Cell Biology | Volume 164, Number 1, 2004
the peroxisome membrane required for its appropriate dock-
ing and the subsequent steps of membrane protein insertion.
Therefore, the assumption that all of the interactions of a
PMP import receptor must be with cargo molecules is un-
likely to be true.
In summary, there is no credible evidence or argument
that PEX19 does not or cannot function as a cytosolic chap-
erone for newly synthesized PMPs or as an import receptor
for PMPs. Rather, the data presented in this paper offer sig-
nificant mechanistic evidence that PEX19 does function as
bifunctional chaperone/import receptor for class I PMPs. In
addition, the data presented here also suggest the existence
of a second, PEX19-independent PMP import pathway.
Materials and methods
Plasmids
The plasmids pcDNA3-PMP34aa244-307/3xmyc, pcDNA3-PMP34aa254-
307/3xmyc, pcDNA3-PMP34aa260-307/3xmyc, pcDNA3-PMP34aa270-
307/3xmyc, pcDNA3-PMP34aa244-303/3xmyc, pcDNA3-PMP34aa244-
291/3xmyc, pcDNA3-PMP34aa254-291/3xmyc, pcDNA3-PMP34aa254-
303/3xmyc, p3xNLS-PEX19 (Jones et al., 2001), pcDNA3- N180-
PEX11 myc, pcDNA3- C535PMP70myc, pcDNA3- C598PMP70myc,
pcDNA3-PMP34myc, pcDNA3-PEX19 (Sacksteder et al., 2000), pNmyc-
PTE1 (Jones et al., 1999), and pcDNA3-PEX11 myc (Schrader et al., 1998)
have been described. New plasmids were generated by PCR amplification of
the appropriate ORF region with primers that append a 5  Asp718 site, a 5 
start codon where necessary, and either a 3  BamHI or 3  BglII site. PCR
products were then inserted into the corresponding sites in the base vectors
pcDNA3/3xmyc (Geisbrecht et al., 1998), pcDNA3/13xmyc (Jones et al.,
2001), or pcDNA3/6xmet3xmyc. The plasmid pcDNA3/6xmet3xmyc is a
modified form of pCDNA3/3xmyc designed to express proteins upstream of
and in fusion with the sequence NH3-GSMMGMMKMMRS-COOH fol-
lowed by three consecutive c-myc epitopes. For mutagenesis in the plas-
mids  pcDNA3-PMP34aa244-307EK289-290LL/3xmyc and pcDNA3-
PMP34aa244-307KR300-301EE/3xmyc, the 3  primers 5 -CCCGGATCC-
GTGTTGGTGTGCACGCTTAGCCCCATAACTGTGAAGGTGGCAGCTGTC-
AGTAACAGATAAACAAGGAAC-3  and 5 -CCCGGATCCGTGTTGGTGT-
GCTTCCTCCAGCCCCATAACTGTG-3 , respectively, were used (BamHI
sites underlined, altered bases in bold). The plasmid pcDNA3-PMP34aa244-
307LMF283-285KKK/3xmyc was made using the 5  primer 5 -CTGCT-
GCAGACAGTCCTCACTGCTGCTAAGAAGAAGCTTGTTTATGAG-3  (PstI
site underlined, altered bases in bold) and a 3  primer with a BamHI site and
insertion between the PstI and BamHI sites of pcDNA3-PMP34aa224-307/
3xmyc. Inserts for the plasmids pcDNA3-PMP34aa270-307KR300-301EE/
3xmyc, pcDNA3-PMP34aa270-307LMF283-285KKK/3xmyc, and pcDNA3-
PMP34aa270-307EK289-290LL/3xmyc were created by amplification from
the above palsmids. All constructs were sequenced to ensure that no unin-
tended mutations were introduced.
Cell lines, transfections, and immunofluorescence studies
The cell lines used in this paper were wild-type human fibroblasts (GM
5756-TI), the PEX3-deficient fibroblast line PBD400-TI, and the PEX19-
deficient fibroblast line PBD399-TI. These are immortalized derivatives of
5756-T, PBD400-T (South et al., 2000), and PBD399-T (Sacksteder et al.,
2000) cells, and were generated by stable transfection with a vector that
constitutively expresses human telomerase (pBabePuro/hTERT; Hahn et
al., 1999). Cells were cultured, transfected, and processed for immunoflu-
orescence as described (Chang et al., 1997). We used the following anti-
bodies: an anti–c-myc mAb from the mouse hybridoma line 1-9E10
(Roche), sheep anti-PMP70 antibodies (South et al., 2000), rabbit anti-
PEX19 antibodies (Sacksteder et al., 2000), anti-catalase antibodies (The
Binding Site), and polyclonal anti-HA antibodies (Santa Cruz Biotechnol-
ogy, Inc.). Fluorescent secondary antibodies used either FITC or Texas red
fluorochromes and were from Jackson ImmunoResearch Laboratories.
Immunofluorescence images were obtained on an BH2-RFCA micro-
scope (Olympus) with an Olympus SplanApo 60x 0.40 oil objective and a
Sensicam QE (Cooke) digital camera using IPLab 3.6.3 software (Scanalyt-
ics, Inc.) at room temperature. Images were imported into Photoshop 7.0
software (Adobe Systems, Inc.) for figure use, and contrast was adjusted to
approximate the original IPLab image.
Immunoblots, cell lysates, immunoprecipitations, 
pulse-chase studies
We used the Bradford protein assay (Bio-Rad Laboratories) for protein
quantification and Complete
TM protease inhibitor cocktail (Roche Diagnos-
tics) for protease inhibition. For immunoprecipitation experiments, tubes
were pretreated with 10 mg/ml BSA and preclear was with 15  l of protein
G agarose for 30 min at 4 C. Immunoblots were performed using standard
protocols and the following antibodies: rabbit anti-PEX19 antibodies
(Sacksteder et al., 2000), rabbit anti-PEX5 antibodies (Dodt et al., 1995),
rabbit anti-c-myc antibodies (Santa Cruz Biotechnology, Inc.), and mouse
monoclonal anti–VSV-G antibodies obtained from C. Machamer (The
Johns Hopkins University School of Medicine). Rabbit anti-PEX13 antibod-
ies were generated against the COOH-terminal 13 aa of human PEX13.
For comparison of cytosolic PMP levels, PEX3-deficient PBD400-TI
cells were transfected with the appropriate PMP expression plasmid and
pcDNA3-PEX19. PEX19-deficient PBD399-TI cells were transfected with
the appropriate PMP expression plasmid and vector alone. 1 d later, cells
were washed in PBS, lysed by harsh resuspension in 400  l hypotonic lysis
buffer (10 mM Tris HCl, pH 7.5, 1 mM EDTA, protease inhibitors), and
centrifuged at 200,000 g for 30 min. Equal amounts of total protein from
supernatant were analyzed by immunoblot.
For immunoprecipitations, PBD400-TI cells were transfected with the
appropriate PMP or mPTS expression plasmid and either pN3xHA-PEX19
or pcDNA3-PEX19. Cells were washed, lysed, and centrifuged as in the
previous paragraph. Equal total protein from each supernatant was brought
to a final volume of 1 ml with PBS. Lysates were precleared and samples
were incubated for 3 h at 4 C with 15  l of anti-HA mAb agarose beads
(Santa Cruz Biotechnology, Inc.). Beads were washed three times in PBS
and PMPs were detected by immunoblot.
For the determination of PEX19’s affect on the stability of PMP34/
13xmyc, PEX3-deficient PBD400-TI cells were transfected with pcDNA3-
PMP34/13xmyc and pcDNA3-PEX19, whereas PEX19-deficient PBD399-
TI cells were transfected with pcDNA3-PMP34/13xmyc and vector alone.
Cells were divided into five equal fractions, incubated overnight in com-
plete medium, incubated for 1 h in methionine-free medium, pulsed for 15
min with 2 ml of methionine-free medium containing 0.5 mCi 
35S-labeled
methionine per fraction, and chased with excess cold methionine. Cells
were washed in cold PBS, lysed, and centrifuged as above. The entire su-
pernatant from each sample was brought to 1 ml with PBS plus 0.5% Tri-
ton X-100. Lysates were precleared then incubated for 3 h at 4 C with 15
 l of anti-myc antibody agarose beads (Santa Cruz Biotechnology, Inc.).
Beads were washed three times in PBS plus 0.5% Triton X-100 and ana-
lyzed by autoradiography and immunoblot.
For the detection of PEX19–PMP interaction during PMP biogenesis,
PEX19-deficient PBD399-TI cells were made to stably express 3xHA-PEX19
by transfection with pN3xHA-PEX19 and selection with 400  g/ml G418.
Cells were transfected with pcDNA3-PMP34/13xmyc, separated into eight
equal fractions, incubated overnight in complete medium, incubated in me-
thionine-free medium for 1 h, pulsed for 10 min with 0.66 mCi per sample,
and chased with excess methionine. Cells were washed twice in ice-cold
PBS and resuspended in cold STE (250 mM sucrose, 10 mM Tris, pH 7.5, 1
mM EDTA, protease inhibitors). Cells were lysed using a ball bearing ho-
mogenizer and centrifuged at 3,000 g for 5 min. Supernatants were centri-
fuged at 25,000 g for 30 min and the resulting supernatants were diluted 1:1
in PBS and centrifuged at 200,000 g for 30 min. The resulting supernatants
were precleared and the samples were incubated with 15  l of anti-HA anti-
body beads for 16 h at 4 C. Beads were pelleted, washed in PBS, resus-
pended in 100  l of release buffer (1% SDS, 50 mM Tris, pH 7.5, and 1 mM
EDTA), and heated in boiling water for 10 min. The beads were pelleted and
the supernatant was brought to 1 ml in 2% BSA, 50 mM Tris, pH 7.5, 1 mM
EDTA. Samples were incubated with 15  l of anti-myc antibody beads for
3 h at 4 C. The beads were pelleted, washed once in 0.1% SDS, 2% BSA, 50
mM Tris, pH 7.5, 1 mM EDTA, twice in PBS plus 1% Triton X-100, and ana-
lyzed by autoradiography and immunoblot.
Studies using siRNA-mediated inhibition
The following RNA oligonucleotide pairs (Dharmacon Research, Inc.)
were used in the creation of siRNA duplexes according to the manufac-
turer’s instructions: PEX19, 5 -GAGAUCGCCAGGAGACACUdTdT-3 ,
5 -AGUGUCUCCU-GGCGAUCUCdTdT-3 ;  PEX5, 5 -AGAAGCUAC-
UCCCAAAGGCdTdT-3 , 5 -GCC-UUUGGGAGUAGCUUCUdTdT-3 ;
TRIP8b, 5 -GCAGGGAAAAGGCUCUAG-GdTdT-3 , 5 -CCUAGAGC-
CUTTTCCCUGCdTdT-3 . 50  l of a 20  M RNA duplex stock in anneal-
ing buffer (100 mM KAc, 30 mM Hepes-KOH, pH7.4, and 2 mM MgAc)
was mixed with normal human fibroblasts (GM 5756-TI) from a confluent
75 cm
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mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4, and 6 mM dextrose). Cells were
electroporated (model BTX ECM600; Genetronics) at 220 V, 1,500  F,
129  . For characterization of siRNA effect on cell phenotype, cells were
grown for 5 d after siRNA treatment. Every 24 h, samples of cells were ei-
ther fixed in 3% formaldehyde or stored at –20 C for study by immunoflu-
orescence or immunoblot.
For assay of peroxisomal protein import in siRNA-treated cells, cells
were treated a second time with siRNA at 16 h after initial treatment to
optimize treatment efficiency. At 60 h after initial siRNA treatment, cells
were transfected with pNHA-PTE1 and either pcDNA3-PMP34myc,
pcDNA3-PMP34aa244-307/3xmyc, pcDNA3-PEX16aa221-336/3xmyc, or
pcDNA3-PEX3aa1-50/6xmet3xmyc. 100 min after this transfection cells
were processed for immunofluorescence. For comparison of PEX19 and
PEX5 siRNA effects on import, all cells showing import of either marker
were scored as to whether they imported HA-PTE1, PMP34myc, or both.
For the comparison of PEX19 siRNA effects on mPTS targeting, cells im-
porting HA-PTE1 were scored as to whether the mPTS-containing protein
was imported into peroxisomes, was only seen in nonperoxisomal com-
partments, or was not seen. This methodology ensured that only those cells
with intact, import-competent peroxisomes were scored.
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